entertainment -WSS

entertainment

author：entertainment 2025-09-30 00:01:01 - browse：11954

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Cherokee Nation medical school graduates its first class

leisure time

WSS

A new House health package & hospitals’ new site

Listen: Biogen's potential pivot, & Illumina's next chapter

House transparency, PBM reform bill gains bipartisan support

ALS treatment from Biogen, Ionis fails in study

Cherokee Nation medical school graduates its first class

The United States must get value

entertainment

entertainment

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Amazon on where the company's health care bets are headed next

Hollywood unions extend contract negotiations for actors

Amazon on where the company's health care bets are headed next

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

STAT series 'Denied by AI' wins major journalism prizes

Bright Health sells Medicare Advantage business to Molina

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Novavax promises a turnaround & Lilly roils the obesity market

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

hotspot

AstraZeneca chief proposes a novel edit to the drug pricing bill

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Illumina names Agilent executive as new CEO

Snackable artificial intelligence, expert AI, and the pharma industry

NIH nominee Bertagnolli will get October confirmation hearing

Hottest summer in 2,000 years puts focus on extreme heat, health

focus

leisure time

explore

focus